136 related articles for article (PubMed ID: 37831536)
1. Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
Huang R; Zhang Z; Wang J; Zhang S; Wu C
Aliment Pharmacol Ther; 2023 Nov; 58(9):965-966. PubMed ID: 37831536
[No Abstract] [Full Text] [Related]
2. Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
Zhao J
Aliment Pharmacol Ther; 2023 Nov; 58(9):964. PubMed ID: 37831535
[No Abstract] [Full Text] [Related]
3. Letter to the editor: Hepatitis B virus genotype: A significant risk factor in determining which patients with chronic hepatitis B virus infection should undergo surveillance for hepatocellular carcinoma: The hepatitis B Alaska study.
Kumar A; Rajani D; Kumar S
Hepatology; 2022 Sep; 76(3):E63-E64. PubMed ID: 35478185
[No Abstract] [Full Text] [Related]
4. Letter to the Editor: Statins and Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Huang R; Wang J; Wu W; Yan X; Wu C
Hepatology; 2020 Jun; 71(6):2173-2174. PubMed ID: 31858599
[No Abstract] [Full Text] [Related]
5. Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
Huang R; Liu J; Wang J; Yan X; Wu C
Aliment Pharmacol Ther; 2021 Mar; 53(6):761-762. PubMed ID: 33599329
[No Abstract] [Full Text] [Related]
6. Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B-authors' reply.
Kim GA; Lim YS
Aliment Pharmacol Ther; 2021 Mar; 53(6):763. PubMed ID: 33599320
[No Abstract] [Full Text] [Related]
7. Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B.
Gattani M; Ingle M; Chauhan S; Lad S
Aliment Pharmacol Ther; 2020 Sep; 52(5):911-912. PubMed ID: 32852812
[No Abstract] [Full Text] [Related]
8. Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations.
Cargill Z; Brown SE; Dusheiko G; Agarwal K
Gut; 2021 Mar; 70(3):629-630. PubMed ID: 32606207
[No Abstract] [Full Text] [Related]
9. [Effect of chronic hepatitis B virus DNA negative transformation and HBsAg clearance on the occurrence of hepatocellular carcinoma].
Zhou JL; Wang BQ; Shi YW; You H
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):831-833. PubMed ID: 31941236
[TBL] [Abstract][Full Text] [Related]
10. On-treatment predictors of hepatocellular carcinoma in patients with chronic hepatitis B.
Peng CY; Chen CH
Liver Int; 2021 Jul; 41(7):1700-1701. PubMed ID: 33966332
[No Abstract] [Full Text] [Related]
11. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Lee HA; Seo YS; Kim SU
Gastroenterology; 2020 Jun; 158(8):2310-2311. PubMed ID: 32201178
[No Abstract] [Full Text] [Related]
12. Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors' reply.
Lee HA; Kim SU
Aliment Pharmacol Ther; 2020 Sep; 52(5):913-914. PubMed ID: 32852833
[No Abstract] [Full Text] [Related]
13. Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?
Kamal F; Khan MA
Gastroenterology; 2020 Jun; 158(8):2311-2312. PubMed ID: 32201182
[No Abstract] [Full Text] [Related]
14. Prevention of hepatocellular carcinoma resulting from hepatitis B: are we there yet?
Di Bisceglie AM
Clin Gastroenterol Hepatol; 2014 May; 12(5):894-6. PubMed ID: 24316105
[No Abstract] [Full Text] [Related]
15. [Screening and surveillance for hepatocellular carcinoma in patients with chronic hepatitis B virus infection].
Expert Group for Project of Hepatocellular Carcinoma Screening and Surveillance, Chinese Foundation for Hepatitis Prevention and Control
Zhonghua Gan Zang Bing Za Zhi; 2021 Oct; 29(10):932-941. PubMed ID: 34814387
[TBL] [Abstract][Full Text] [Related]
16. Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy-authors' reply.
Fan R; Hou J
Aliment Pharmacol Ther; 2021 Sep; 54(5):724-725. PubMed ID: 34379840
[No Abstract] [Full Text] [Related]
17. Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page?
Sonneveld MJ; Brouwer WP; de Man RA
J Hepatol; 2020 Sep; 73(3):728-729. PubMed ID: 32423630
[No Abstract] [Full Text] [Related]
18. Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page".
Chan HL; Wong VW; Yip TC; Wong GL
J Hepatol; 2020 Sep; 73(3):729-730. PubMed ID: 32423634
[No Abstract] [Full Text] [Related]
19. Letter to the Editor: Is HBV genotype strongly associated with HCC risk in patients with chronic hepatitis B?
Huang R; Liu J; Wang J; Li J; Wu C
Hepatology; 2022 Jan; 75(1):233-234. PubMed ID: 34519071
[No Abstract] [Full Text] [Related]
20. Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.
Pol S; Luzivika Nzinga C; Fontaine H; Carrat F;
Aliment Pharmacol Ther; 2021 Mar; 53(5):659. PubMed ID: 33566398
[No Abstract] [Full Text] [Related]
[Next] [New Search]
